Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart in moderate to severe bullous pemphigoid
NCT07210554Phase 3Not yet recruiting
- Sponsor
- Chengdu Kangnuoxing Biopharma, Inc.
- Start
- Nov 2025
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of stapokibart in Bullous Pemphigoid (BP), sponsored by Chengdu Kangnuoxing Biopharma, Inc.. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
stapokibart
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NCT07210554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07210554.